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Background. The goal of targeted antiretroviral therapy initiation is to minimize disease progression among pa-
tients with human immunodeficiency virus while minimizing the therapeutic burden on these patients. We examine
whether the effect of delaying therapy initiation from 500 cells/mm3 to 350 or 200 cells/mm3 is modified by age at
entry into care.
Methods. We used the parametric g-formula to compare 10-year mortality under 3 CD4 cell count thresholds
for therapy initiation among 3532 patients who entered care at 1 of 8 sites in the United States between 1998 and
2013. Results are reported separately for patients 18 to 34, 35 to 44, and 45 to 65 years of age at study entry.
Results. In the observed data, 10-year mortality was 13% (165 deaths). Mortality increased from 11% under ther-
apy initiation at 500 cells/mm3 to 12% at 350 cells/mm3 (risk difference [RD]: 0.87; 95% confidence interval [CI]: .56,
2.17) and to 14% at 200 cells/mm3 (RD: 2.71; 95% CI: 1.79, 5.38). The effect of delaying therapy became greater with
age: RDs comparing the 350-cells/mm3 threshold with the 500-cells/mm3 threshold ranged from −0.03 (95% CI:
−0.15, 1.76) for patients 18 to 34 years of age to 0.99 (95% CI: −.27, 1.98) for patients 35 to 44 and to 2.30 (95%
CI: 1.29, 5.42) for patients 45 to 65.
Conclusions. Delaying therapy increased 10-year mortality in the full cohort. Subgroup analysis highlights that
patients entering care at older ages may be more vulnerable to the consequences of delayed ART initiation than
younger patients.
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Several recent large-scale observational studies have ad-
dressed when to initiate antiretroviral therapy (ART)
with respect to CD4 cell count. The goal of targeted
ART initiation is to minimize disease progression or
mortality among people living with human immunodefi-
ciency virus (HIV) [1–5]. These studies have reported
heterogeneous optimal CD4 cell count thresholds be-
tween 300 and 500 cells/mm3 [1, 3–5] as well as thresh-
olds over 500 cells/mm3 [2]. From a public health
perspective, any unexplained heterogeneity in this evi-
dence base is largely outweighed by the randomized ev-
idence that early initiation of therapy reduces rates of
HIV transmission [6], which has led to recent guidelines
recommending treatment for all patients in care for HIV.
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Nevertheless, advanced age has been a durable marker for
more rapid disease progression and mortality in both the natu-
ral [7] and treated [8] histories of HIV infection. In the above-
referenced observational studies, average age at study entry
varied from 28 years [3] to 40 years [2]. Alterations in immune
function over the life span support the hypothesis that HIV
pathogenesis accelerates aging, with earlier occurrence of
AIDS and non–AIDS-related events. Early therapy initiation
in older patients could have a greater benefit than that reported
for all ages combined. To date, there has been no report on pos-
sible age modification of the optimal CD4 cell count to initiate
ART. Here, we report age-stratified 10-year mortality in the
Centers for AIDS Research Network of Integrated Clinical Sys-




The CNICS was developed to support population-based HIV re-
search in the United States [9].The CNICS cohort includes 26 405
HIV-positive adults engaged in clinical care from 1 January 1998
to December 31, 2013 at 8 Centers for AIDS Research sites (Case
Western Reserve University; Fenway Community Health Center
of Harvard University; Johns Hopkins University; University of
Alabama at Birmingham; University of California, San Diego;
University of California, San Francisco; University of North Caro-
lina; and University of Washington). Patients attending 2 primary
HIV medical care visits at a study site are eligible for CNICS and
followed for clinical events, lab measurements, and medications
while they remain in care at study sites. Institutional review boards
at each site approved study protocols. Patients provided written
informed consent to be included in the CNICS cohort or contrib-
uted administrative and/or clinical data with a waiver of written
informed consent where approved by local institutional review
boards. Details on the CNICS cohort are provide elsewhere [9].
Patients who entered HIV clinical care at a CNICS site be-
tween 1 January 1998 and 31 December 2013 and had not pre-
viously initiated combination ART, defined as treatment with 3
or more antiretroviral drugs, were eligible for inclusion in this
analysis (N = 19 384). We included only patients with CD4 cell
counts >500 cells/mm3 and a detectable viral load at baseline
(N = 3734), as patients with undetectable viral load at baseline
were likely not therapy naive. Patients were excluded if they
were missing information on transmission risk factor, race, or
sex (n = 202), leaving 3532 patients in the cohort for analysis.
Patients were followed from entry into care at a CNICS site until
death, loss to follow-up, or administrative censoring at 10 years
after study entry or 31 December 2013. Patients were considered
to be lost to follow-up after 12months without a documented clin-
ic visit in which CD4 cell count or viral load was measured.
Mortality Ascertainment
The outcome of interest was mortality from any cause. Each
CNICS site maintains a registry of deaths among patients at
that site and semiannually queries the US Social Security
Death Index and/or National Death Index to confirm reported
deaths and record deaths not captured by the CNICS sites.
Statistical Methods
We compared the 10-year cumulative incidence of all-cause mor-
tality under the following 3 dynamic treatment plans: initiate ART
at first visit when CD4 cell count is <500 cells/mm3; initiate ART
at first visit when CD4 cell count is <350 cells/mm3; and initiate
antiretroviral therapy at first visit when CD4 cell count is <200
cells/mm3. We perform these comparisons separately for patients
in each of the following 3 age ranges at study entry: 18 to 34
(n = 1744), 35 to 44 (n = 1132), and 45 to 65 years of age (n = 627).
The dynamic treatment regimes outlined above require pa-
tients to start therapy immediately after CD4 cell count drops
below the threshold value. In practice, immediate therapy initia-
tion may not be possible. To address possible delays in treatment,
we follow existing work [4, 5] and examine the 10-year mortality
under 3 dynamic treatment plans that incorporate a 6-month
“grace period” between the CD4 cell count threshold and therapy
initiation. These treatment plans take the form “initiate antiretro-
viral therapy 6 months after CD4 cell count first drops below the
threshold value or the time at which the patient would have ini-
tiated therapy during the grace period with no intervention on
treatment plan (ie, when the patient was expected to initiate treat-
ment in the observe data), whichever comes first.”
We estimated the 10-year cumulative incidence of mortality
under the 3 specified dynamic treatment plans with and with-
out the grace period using the parametric g-formula, as de-
scribed by Young et al [5]. Under the assumptions of no
measurement error, conditional exchangeability, positivity,
and no model misspecification, the parametric g-formula pro-
vides consistent estimates of the risk of mortality under each dy-
namic treatment plan. The g-formula accounts for time-fixed
and time-varying confounders through a generalization of
standardization in which we estimate the density of all possible
covariate histories and sum the risk of mortality over these co-
variate histories [10, 11]. Briefly, to implement the parametric
g-formula, we model the probability of treatment, time-varying
confounders, and mortality at each time point conditional on
covariates in the observed data. Then, we use these conditional
probabilities to estimate the risk of mortality by time t that
would have been observed if we had set exposure according to
each treatment plan and observed all participants until death or
the end of the study. Time-fixed covariates included in our anal-
ysis were sex, race, ethnicity, injection drug use, men who have
sex with men (MSM) status, and age, year, CD4 cell count, and
viral load at study entry. Time-varying covariates included CD4
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cell count, viral load, and AIDS status at each clinic visit. Con-
tinuous variables were modeled flexibly using restricted qua-
dratic splines. Full technical details are provided in the
Supplementary Appendix.
Risk of mortality under each treatment plan at time t (regardless
of actual treatment use at time t) was estimated using the comple-
ment of the Kaplan–Meier survival curve [12].Mortality was com-
pared between treatment plans using risk ratios (RRs) and risk
differences (RDs), and 95% confidence intervals (CIs) were esti-
mated using the standard deviation from 500 nonparametric boot-
strap samples [13] as an approximation of the standard error. RRs,
RDs, and corresponding 95% CIs were estimated separately for
patients 18 to 34, 35 to 44, and 45 to 65 years of age.
RESULTS
Of the 3532 ART-naive patients who entered care at a CNICS
site with a CD4 cell count >500 cells/mm3, 82% (n = 2886) were
male, 34% (n = 1194) were black, 17% (n = 581) were injection
drug users, and 67% (n = 2359) were MSM. Patients entered the
cohort between 1998 and 2013, and the median year of entry
was 2006 (interquartile range [IQR]: 2002, 2009). At study
entry, the median CD4 cell count of eligible patients was 646
cells/mm3 (IQR: 567, 780) and the median viral load was
11 722 copies/mL (IQR: 3473, 43 000).
Table 1 presents the distribution of baseline characteristics
among all patients and patients in each age group. Median
CD4 cell count at study entry was similar among patients enter-
ing care at 18 to 34 (median: 647 cells/mm3; IQR: 566, 782), 35
to 44 (median: 648 cells/mm3; IQR: 567, 788), and 45 to 65
years of age (median: 638 cells/mm3; IQR: 568, 782). Patients
entering care during the study period at younger ages were
more likely to be male, Hispanic, and MSM than older patients,
while patients entering care at older ages were more likely to be
injection drug users and have an AIDS diagnosis.
Patients in all age groups at study entry were most likely to
initiate ART with a CD4 cell count >500 cells/mm3, though
some patients in each age group initiated ART at lower CD4
cell counts. Over the follow-up period, 165 deaths occurred, in-
cluding 29 among patients in the 18 to 34 age group, 65 in the
35 to 44 age group, and 66 in the 45 to 65 age group. Five deaths
occurred among patients who entered care after age 65 and were
excluded from subgroup analyses. The overall cumulative inci-
dence of mortality was 5% at 5 years and 13% at 10 years.
Table 2 compares the 5- and 10-year cumulative incidence of
mortality for the eligible patients under no intervention and the
Table 1. Demographics and Clinical Characteristics at Study Entry Among 3532 Patients Who Entered Care With a CD4 Cell Count
>500 cells/mm3 Between 1 January 1998 and 31 December 2013 at 8 US Clinical Sites, Followed for Death for Up to 10 Years
Characteristic
All Patients at
Study Entry (n = 3532)
18–34 Years of Age at
Study Entry (n = 1744)
35–44 Years of Age at
Study Entry (n = 1132)
45–65 Years of Age at
Study Entry (n = 627)
n (%) % % %
Male 2886 (82.1) 83.8 81.3 78.9
Black 1194 (34.0) 32.7 33.0 38.9
Hispanic ethnicity 329 (9.4) 11.6 7.8 6.2
Injection drug user 581 (16.5) 12.3 20.2 21.9
Men who have sex with men 2359 (67.1) 73.8 64.2 54.5
AIDS 189 (5.4) 3.6 6.3 8.6
CD4 cell count at entry, cells/mm3
500–600 1292 (36.8) 37.2 35.0 38.6
601–750 1180 (33.8) 33.4 34.3 32.5
751–1000 786 (22.5) 22.3 23.6 20.4
>1000 257 (7.31) 7.1 7.2 8.5
CD4 cell count at initiation of ART, cells/mm3
0–200 92 (2.6) 1.9 3.3 3.2
201–350 293 (8.3) 6.2 10.8 10.0
351–500 374 (10.6) 10.3 10.4 11.5
>500 1052 (29.9) 30.8 26.5 33.8
Did not initiate ART while in the study 1704 (48.5) 50.1 49.0 41.5
Year at study entry
1998–2002 1013 (28.8) 25.7 35.8 25.0
2003–2007 1154 (32.8) 30.7 36.1 32.5
2008–2013 1348 (38.3) 43.6 28.1 42.4
Abbreviation: ART, antiretroviral therapy.
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3 dynamic treatment plans for each age group. Overall, 10-year
mortality was elevated if patients initiated ARTwithin 6 months
of CD4 cell count dropping to <350 cells/mm3 (mortality =
12%) compared with if all patients initiated ART within 6
months of CD4 cell count dropping to <500 cells/mm3 (mortal-
ity = 11%), for an RR of 1.08 (95% CI: 1.00, 1.16) and an RD of
0.87% (95% CI: .07, 1.67). Ten-year mortality was further ele-
vated to 14% if patients waited to initiate ART within 6 months
of CD4 cell count dropping to <200 cells/mm3, for an RR of
1.25 (95% CI: 1.08, 1.44) and an RD of 2.71% (95% CI: .92,
4.50). Figure 1 illustrates the cumulative incidence of mortality
over 10 years for each of the treatment plans.
Table 2 also compares the estimated mortality under each treat-
ment plan by age group. Patients who entered care at 18 to 34 years
of age had the lowest estimated 10-year mortality for each treat-
ment plan. In these patients, mortality was similar regardless of
the CD4 cell count threshold used as a trigger for ART initiation.
The 10-year mortality for patients entering care at 35 to 44
years of age was 11% under ART initiation within 6 months
of CD4 cell count dropping to <500 cells/mm3. Mortality in-
creased slightly under the 350-cells/mm3 threshold (RR: 1.09;
95% CI: .99, 1.20; RD: 0.99%; 95% CI: −.13, 2.11) and the
200-cells/mm3 threshold (RR: 1.19; 95% CI: 1.98, 1.45; RD:
2.15%; 95% CI: −.39, 4.69).
As expected, patients who entered care at 45 to 65 years of age
experienced the highest 10-year risk of mortality under all
treatment plans. Under the 500-cells/mm3 threshold for ART
initiation, the 10-year mortality was 19%. The 10-year risk of
mortality increased to 22% under the 350-cells/mm3 threshold
Figure 1. Standardized cumulative incidence of mortality under 3 dy-
namic treatment plans with a 6-month grace period among 3532 patients
who entered care between 1 January 1998 and 31 December 2013 at 8 US
clinical sites with a CD4 cell count >500 cells/mm3, followed for death for
up to 10 years.
Table 2. Standardized 5- and 10-Year Cumulative Incidence of Mortality Under no Intervention and 3 Dynamic Treatment Plans With a
6-Month Grace Period Among 3532 Patients Who Entered Care Between 1 January 1998 and 31 December 2013 at 8 US Clinical Sites,
Followed for Death for Up to 10 Years
Treatment Plan
5-year 10-year
Mortality RR 95% CI RD 95% CI Mortality RR 95% CI RD 95% CI
No intervention 5.45 12.60
All ages
500 cells/mm3 4.63 1 0 10.80 1 0
350 cells/mm3 5.30 1.15 1.05, 1.26 0.67 .23, 1.11 11.66 1.08 1.00, 1.16 0.87 .07, 1.67
200 cells/mm3 6.17 1.33 1.15, 1.54 1.54 .72, 2.36 13.51 1.25 1.08, 1.44 2.71 .92, 4.50
18 to 34 years of age
500 cells/mm3 2.11 1 0 6.11 1 0
350 cells/mm3 2.22 1.05 .87, 1.27 0.11 −.33, .55 6.08 1.00 .87, 1.15 −0.03 −.83, .77
200 cells/mm3 2.45 1.16 .84, 1.60 0.34 −.40, 1.08 6.25 1.02 .78, 1.33 0.14 −1.48, 1.76
35 to 44 years of age
500 cells/mm3 5.09 1 0 11.43 1 0
350 cells/mm3 5.51 1.08 .95, 1.22 0.42 −.23, 1.07 12.42 1.09 .99, 1.20 0.99 −.13, 2.11
200 cells/mm3 5.76 1.13 .91, 1.41 0.67 −.59, 1.93 13.59 1.19 1.98, 1.45 2.15 −.39, 4.69
45 to 65 years of age
500 cells/mm3 9.17 1 0 19.29 1 0
350 cells/mm3 11.28 1.23 1.08, 1.40 2.11 .80, 3.42 21.60 1.12 1.01, 1.25 2.30 .23, 4.37
200 cells/mm3 14.50 1.58 1.31, 1.90 5.33 3.15, 7.51 28.07 1.45 1.21,1.71 8.78 5.89, 13.90
Abbreviations: CI, confidence interval; RD, risk difference; RR, risk ratio.
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for an RR of 1.12 (95% CI: 1.01, 1.25) or an RD of 2.30% (95%
CI: .23, 4.37). If patients in this group waited to initiate ART
until CD4 cell count was <200 cells/mm3, 10-year mortality
was 28%, yielding an RR of 1.45 (95% CI: 1.21,1.71) and an
RD of 8.78% (95% CI: 5.89, 13.90). Figure 2 depicts the 10-
year mortality under the 3 dynamic treatment plans stratified
by age, demonstrating more dramatic effects of delayed ART
initiation among older patients. The P value for trend in the
RDs by age group was .0498 comparing the 350 and 500 thresh-
olds and 0.2230 comparing the 200 and 500 thresholds.
Results were similar when the dynamic treatment plans did
not include a 6-month grace period, when patients were censored
after a 6- or 18-month (rather than 12-month) gap in care, and
after excluding patients with AIDS diagnosis or mono or dual-
therapy prior to study entry (Supplementary Tables 2–5).
DISCUSSION
The effect of delaying ART initiation on 10-year mortality was
not homogenous among age groups. For patients who entered
care at a CNICS site at 18 to 34 years of age, delaying ART until
CD4 cell count dropped to <200 cells/mm3 had little effect. The
effect of delaying ART was slightly more pronounced among
patients who entered care at 35 to 44 years of age. However,
among patients who entered care at 45 to 65 years of age, delay-
ing ART had a profoundly deleterious effect; delaying ART
until CD4 cell count dropped to <200 cells/mm3 increased
10-year mortality from 19% (had patients initiated ART when
CD4 cell count first dropped to <500 cells/mm3) to 28%.
The overall results agree with existing work on “when to
start” ART. As in recent work [1–5], delaying ART initiation
until the CD4 cell count is <200 cells/mm3 resulted in higher
mortality during the 10-year study period. In particular, the
5-year RR comparing the dynamic treatment plan “initiate
ART within 6 months of CD4 cell count dropping below 200
cells/mm3” to “initiate ART within 6 months of CD4 cell count
dropping below 500 cells/mm3” (RR = 1.33) was similar to RRs
presented by Cain [4] (RR = 1.19) and Young [5] (RR = 1.38).
Our approach provides consistent (ie, unbiased) estimates of
the cumulative incidence of mortality under several assump-
tions. First, we assume that all variables (eg, CD4 cell count,
date of treatment initiation, and date of death, among others)
were measured without error. We also assume that patients ini-
tiating treatment at different CD4 cell counts are exchangeable
within levels of measured covariates or that there is no unmea-
sured confounding [14]. For example, in the observed data, only
a small proportion of eligible patients in each age group initiat-
ed ART at CD4 cell counts <200 cells/mm3, and this proportion
decreased over calendar time; if these patients were systemati-
cally different from patients initiating ART at higher CD4 cell
counts, conditional on observed covariates, the estimated cu-
mulative incidence of mortality <200 cells/mm3 treatment
threshold could be biased.
Similarly, we assume that right censoring is ignorable condi-
tional on measured covariates [15]. Though loss to follow-up
was high (over the 10-year study period, 56% of patients were cen-
sored due to a 1-year or greater gap in lab measurements), few
measured variables predicted loss to follow-up and the proportion
lost to follow-up was similar across the age groups, though pa-
tients in the oldest age group were somewhat less likely to be
lost (Supplementary Table 8). In addition, previous work has
shown that loss to follow-up in the CNICS cohort does not predict
mortality [16], indicating that selection bias resulting from the
high proportion of patients lost to follow-up is likely to bemodest.
We used parametric models for treatment, time-varying co-
variates, and mortality, and the validity of our results depends
on correct specification of these models. Though it is not pos-
sible to check the performance of the models under the
Figure 2. Standardized cumulative incidence of mortality under 3 dynamic treatment plans with a 6-month grace period among 1744 patients who en-
tered care at 18 to 34 years of age (A), 1132 patients who entered care at 35 to 45 years of age (B), and 627 patients who entered care at 45 to 65 years of
age (C) between 1 January 1998 and 31 December 2013 at 8 US clinical sites, followed for death for up to 10 years.
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intervention scenarios, we note agreement between the ob-
served time to mortality and values of the covariates and the
predicted values from our models under no intervention (Sup-
plementary Figure 1).
We excluded patients who entered care in CNICS with a CD4
cell count <500 cells/mm3 so that we could compare the 10-year
mortality had we implemented treatment plans to initiate ART
at 500, 350, and 200 cells/mm3 in the same group of patients
and so that we could compare our results to those from existing
studies. Because these patients compose only roughly 20% of
the therapy-naive population of CNICS and unmeasured vari-
ables such as predictors of health-seeking behaviors likely pre-
dict both early entry into care and mortality, our results may not
be generalizable to the entire CNICS population [17]. In addi-
tion, including only patients entering with CD4 cell counts
>500 cells/mm3 likely preferentially captures a slow progression
population, as “slow progressors” have more time to enter care
before CD4 cell count drops below this threshold.
We did not have information on cause of death or comorbid-
ities. It is possible that the heterogeneity in the estimated effect
of delaying ART initiation by age could be explained, in part, by
differences in the distribution of comorbidities and, therefore,
causes of death for patients entering CNICS in each age
group. For example, we know that a higher proportion of pa-
tients in the older age groups reported injection drug use
(21% in the 45–65 group and 20% in the 34–45 group) than pa-
tients aged 18 to 34 years (12%), meaning that older patients
may have been more likely to be infected with other blood-
borne diseases, such as hepatitis C.
While there are certainly population health benefits to early
ART initiation, the individual, patient-level benefits of initiating
ART at 500 cells/mm3 rather than 350 cells/mm3 or 200 cells/
mm3 are unclear for younger patients in terms of mortality
risk, according to our analyses. Acknowledging that clinical
guidelines increasingly incorporate public health consider-
ations, particularly in light of the efficacy of treatment as pre-
vention approaches [6], medical providers entertain treatment
decisions with individual patients, one at a time. Our findings
suggest that for younger patients entering HIV medical care
with high CD4 counts, there may be less urgency in initiating
ART from the standpoint of individual health outcomes.
These results contribute a new layer of evidence by describing
the variable individual-level benefits of more immediate ART
initiation according to age. Ultimately, treatment decisions
must weigh as many benefits and risks as possible, at an individ-
ual and population health level, and should be made by patient–
provider dyads informed by the best available evidence.
As expected, this study illustrates that delaying ART increases
10-year mortality. Subgroup analysis highlights that adults en-
tering care at 45 to 65 years of age are more vulnerable to the
consequences of delayed ART initiation than younger adults.
While current guidelines recommend early ART initiation for
all adults to improve both individual and population-level
health outcomes, the striking increase in 10-year mortality
under delayed ART initiation for adults older than 45 stresses
the heightened importance of early ART initiation in this
group. Increasing early ART initiation among adults older
than 45 will require both the clinical guidelines already in
place as well as a renewed commitment to improving timely di-
agnosis and linkage to HIV medical care in this population.
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